18 Paul Tudor Jones II Teladoc Health Trades
The first Teladoc Health trade was made in Q2 2018. Since then Paul Tudor Jones II bought shares nine more times and sold shares on eight occasions. The investor sold all their shares in Q4 2024 and doesn't own any shares in Teladoc Health anymore.
Avg closing price
Price range
Sold -440k shares
Q4 2024
Avg closing price
$9.67
Price range
$8.57
-
$12.02
New holding (+440k shares)
Q3 2024
Avg closing price
$8.27
Price range
$6.79
-
$10.09
Sold -44.3k shares
Q4 2023
Avg closing price
$18.45
Price range
$15.57
-
$22.10
Sold 78.9% shares (-166k shares)
Q3 2023
Avg closing price
$23.34
Price range
$18.53
-
$29.77
Increased shares by 73.3% (+89k shares)
Q2 2023
Avg closing price
$25.17
Price range
$22.42
-
$28.17
Increased shares by 236.8% (+85.4k shares)
Q1 2023
Avg closing price
$26.76
Price range
$22.29
-
$33.20
Sold 69.9% shares (-83.5k shares)
Q4 2022
Avg closing price
$26.96
Price range
$22.83
-
$33.31
Increased shares by 97.5% (+59k shares)
Q3 2022
Avg closing price
$35.08
Price range
$25.35
-
$43.66
New holding (+60.6k shares)
Q2 2022
Avg closing price
$42.47
Price range
$28.63
-
$75.86
Sold -12.8k shares
Q3 2020
Avg closing price
$211.77
Price range
$183.75
-
$249.42
Increased shares by 53.2% (+4.43k shares)
Q2 2020
Avg closing price
$175.25
Price range
$139.10
-
$204.94
Sold 78.0% shares (-29.6k shares)
Q1 2020
Avg closing price
$116.34
Price range
$82.96
-
$167.44
Increased shares by 93.8% (+18.4k shares)
Q4 2019
Avg closing price
$76.10
Price range
$61.54
-
$85.88
New holding (+19.6k shares)
Q3 2019
Avg closing price
$65.81
Price range
$55.30
-
$72.20
Sold -36.8k shares
Q1 2019
Avg closing price
$61.05
Price range
$46.23
-
$69.99
Increased shares by 184.3% (+23.9k shares)
Q4 2018
Avg closing price
$61.19
Price range
$42.88
-
$83.72
Sold 56.1% shares (-16.5k shares)
Q3 2018
Avg closing price
$71.27
Price range
$59.40
-
$86.35
New holding (+29.5k shares)
Q2 2018
Avg closing price
$48.84
Price range
$38.50
-
$62.35
News about Teladoc Health Inc and Paul Tudor Jones II
Teladoc Welcomes Charles Divita as CEO with Strong Support Plan
An update from Teladoc (TDOC) is now available. Charles Divita, III has taken the helm as Teladoc Health, Inc.¡¯s CEO, with Mala Murthy returning to¡
Q&A with PlushCare co-founder and CEO Ryan McQuaid on the Teladoc-Livongo merger, Amazon Care, and the future of telehealth
Summary List Placement Teladoc shook the virtual care landscape up when it merged with digital therapeutics firm Livongo in a $18.5 billion deal in October, ...